Mysore Petro (506734)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 1/1

Key Financials

Strengths

• Trading at a discount to book value: price ₹165.80 vs book value ₹186.81, P/B 0.89.
• Market cap of ₹109 Cr is below estimated book value of roughly ₹123 Cr, offering a theoretical asset cushion.
• Dividend yield of 2.02% provides some income while waiting for a catalyst.
• Sales growth of 187% indicates expanding business activity, though not yet profitable growth.

Concerns

• Trailing P/E of 1000 signals negligible earnings power relative to price.
• Profit growth of -130.32% and a latest-quarter net loss of ₹2 Cr show deteriorating profitability.
• ROE of 3.76% and ROCE of 7.82% reflect poor returns on capital; no durable competitive advantage evident in a trading business.
• Piotroski F-Score of 4/9 suggests weak financial health and possible balance-sheet stress.

AI Analysis

I look for a business I can understand and a price that gives me margin of safety. Mysore Petro is a chemicals trader; that is a business without pricing power and hardly a durable moat. The figures tell me the market is paying ₹165.80, or ₹109 Cr, for a company whose book value is ₹186.81 per share. That discount to book is the only Graham-like attraction. But book value alone is insufficient; I need earnings power. A trailing P/E of 1000 means earnings of just ₹0.166 per share—negligible. ROE of 3.76% and ROCE of 7.82% show capital is earning very little. Sales growth of 187% looks dazzling, but profit growth of -130.32% and a latest-quarter loss of ₹2 Cr warn that expanding turnover is not translating into the bottom line. This resembles low-quality expansion, not a compounding machine. The Piotroski F-Score of 4/9 reinforces my unease: the fundamentals are deteriorating. A dividend yield of 2.02% is modest compensation. A P/B below 1 can become a value trap if inventories and receivables in a trading business are overstated or if losses continue. Without promoter holding or debt/equity data, I cannot assess insider alignment or leverage risk. In Buffett's words, it is far better to buy a wonderful business at a fair price than a fair business at a wonderful price. Here the business is unproven, and the price is low only by book value, not by earnings. I would watch whether the latest quarter's loss becomes a trend. If management can convert the 187% sales surge into real margins and consistent profits, this could become a turnaround; until then, it is an asset play requiring caution.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer